Challenges to clinical trials in multiple sclerosis: Outcome measures in the era of disease-modifying drugs

Current Opinion in Neurology

Volumn 24, Issue 3, 2011, Pages 255-261

  Hyland, Megan ^a   Rudick, Richard A ^a,b  

^a NEUROLOGICAL INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

clinical trial; multiple sclerosis; multiple sclerosis functional composite; outcome measure

Indexed keywords

ARTICLE; BRAIN ATROPHY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DISABILITY; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 79955585784     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283460542     Document Type: Article

References (59)

1. Inusah S, Sormani MP, Cofield SS, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler 2010; 16:1414-1421.
2. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7:903-914.
3. AngellM. The ethics of clinical research in the third world. N Engl J Med 1997; 337:847-849. (Pubitemid 27391637)
4. Filippi M, Agosta F. Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging 2010; 31:770-788.
5. Healy BC, Ikle D, Macklin EA, Cutter G. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint. Mult Scler 2010; 16:840-847.
6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452. (Pubitemid 14237132)
7. Kragt JJ, Thompson AJ, Montalban X, et al. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 2008; 70 (13 Pt 2):1084-1091. (Pubitemid 351464764)
8. Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology 2010; 74 (Suppl 3): S8-S15.
9. Vickrey BG, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4:187-206.
10. Twork S, Wiesmeth S, Spindler M, et al. Disability status and quality of life in multiple sclerosis: nonlinearity of the expanded disability status scale (EDSS). Health Qual Life Outcomes 2010; 8:55.
11. Rudick RA, Kappos L. Measuring disability in relapsing-remitting MS. Neurology 2010; 75:296-297.
12. Ebers GC, Heigenhauser L, Daumer M, et al. Disability as an outcome in MS clinical trials. Neurology 2008; 71:624-631.
13. Rudick RA, Lee JC, Cutter GR, et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch Neurol 2010; 67:1329-1335.
14. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functionalcomposite as a clinical trial outcomemeasure. Brain 1999;122 (Pt 5): 871-882. (Pubitemid 29219261)
15. Lowe MJ, Horenstein C, Hirsch JG, et al. Functional pathway-defined MRI diffusion measures reveal increased transverse diffusivity of water in multiple sclerosis. Neuroimage 2006; 32:1127-1133. (Pubitemid 44278668)
16. Kalkers NF, Bergers L, de Groot V, et al. Concurrent validity of the ms functional composite using MRI as a biological disease marker. Neurology 2001; 56:215-219. (Pubitemid 32095363)
17. Rudick RA, Cutter G, Baier M, et al. Use of the multiple sclerosis functional composite to predict disability in relapsing MS. Neurology 2001; 56:1324-1330. (Pubitemid 32455292)
18. Vrenken H, Pouwels PJ, Ropele S, et al. Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler 2007; 13:708-716. (Pubitemid 47074092)
19. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59:679-687.
20. Rudick RA, Polman CH, Cohen JA, et al. Assessing disability progression with the multiple sclerosis functional composite. Mult Scler 2009; 15:984-997.
21. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001; 58:961-967. (Pubitemid 32537471)
22. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
23. Penner IK, Raselli C, Stocklin M, et al. The fatigue scale for motor and cognitive functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 2009; 15:1509-1517.
24. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62:335-346. (Pubitemid 350105948)
25. Daumer M, Neuhaus A, Morrissey S, et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009; 72:705-711.
26. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65:268-275.
27. Petkau J, Reingold SC, Held U, et al. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 2008; 14:770-778.
28. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002; 15:239-245. (Pubitemid 34596884)
29. McFarland HF. Examination of the role of magnetic resonance imaging in multiple sclerosis: a problem-orientated approach. Ann Indian Acad Neurol 2009; 12:254-263.
30. Sormani MP, Bonzano L, Roccatagliata L, et al. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 2010; 75:302-309.
31. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67:944-953. (Pubitemid 44454583)
32. Moraal B, Meier DS, Poppe PA, et al. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology 2009; 250:506-514.
33. Moraal B, van den Elskamp IJ, Knol DL, et al. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. Ann Neurol 2010; 67:667-675.
34. Moraal B, Wattjes MP, Geurts JJ, et al. Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology 2010; 255:154-163.
35. Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000; 6:373-377. (Pubitemid 32106796)
36. Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating- remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995; 1:118-135.
37. van den Elskamp IJ, Boden B, Dattola V, et al. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology 2010; 52:875-881.
38. Polman C, Barkhof F, Kappos L, et al. Oral interferon beta-1a in relapsingremitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003; 9:342-348. (Pubitemid 36958016)
39. Calabrese M, Rinaldi F, Mattisi I, et al. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology 2010; 74:321-328.
40. Nakamura K, Fox R, Fisher E. CLADA: cortical longitudinal atrophy detection algorithm. Neuroimage 2011; 54:278-289.
41. Sormani MP, Rovaris M, Comi G, Filippi M. A composite score to predict short-term disease activity in patients with relapsing-remitting MS. Neurology 2007; 69:1230-1235. (Pubitemid 47429023)
42. Syc SB, Warner CV, Hiremath GS, et al. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler 2010; 16:829-839.
43. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010; 9:921-932.
44. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006; 113:324-332. (Pubitemid 43170783)
45. Frohman EM, Dwyer MG, Frohman T, et al. Relationship of optic nerve and brain conventional and nonconventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci 2009; 282 (1-2):96-105.
46. Zaveri MS, Conger A, Salter A, et al. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol 2008; 65:924-928. (Pubitemid 352008476)
47. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59:963-969. (Pubitemid 43830928)
48. Jeanjean L, Castelnovo G, Carlander B, et al. Retinal atrophy using optical coherence tomography (OCT) in 15 patients with multiple sclerosis and comparison with healthy subjects. Rev Neurol (Paris) 2008; 164:927-934.
49. Merle H, Olindo S, Donnio A, et al. Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Invest Ophthalmol Vis Sci 2008; 49:4412-4417.
50. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology 2009; 73:46-52.
51. Oreja-Guevara C, Noval S, Manzano B, Diez-Tejedor E. Optic neuritis, multiple sclerosis-related or not: structural and functional study. Neurologia 2010; 25:78-82.
52. Siger M, Dziegielewski K, Jasek L, et al. Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol 2008; 255:1555-1560.
53. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, et al. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 2007; 68:1488-1494. (Pubitemid 46685919)
54. Siepman TA, Bettink-Remeijer MW, Hintzen RQ. Retinal nerve fiber layer thickness in subgroups of multiple sclerosis, measured by optical coherence tomography and scanning laser polarimetry. J Neurol 2010; 257:1654-1660.
55. Toledo J, Sepulcre J, Salinas-Alaman A, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler 2008; 14:906-912.
56. Albrecht P, Frohlich R, Hartung HP, et al. Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis. J Neurol 2007; 254:1595-1596. (Pubitemid 50001593)
57. Gordon-Lipkin E, Chodkowski B, Reich DS, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 2007; 69:1603-1609. (Pubitemid 350287144)
58. Schwid SR, Goodman AD, Mattson DH, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology 1997; 49:1419-1424. (Pubitemid 27495653)
59. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5:256-266.